Human urinary kallindinogenase therapy for acute ischemic stroke according to Chinese ischemic stroke subclassification: Clinical efficacy and risk factors
Abstract Introduction To evaluate effectiveness of human urinary kallindinogenase (HUK) in patients with acute ischemic stroke (AIS) according to Chinese ischemic stroke subclassification (CISS) and analyzed risk factors of clinical efficacy. Methods In this retrospective study, 134 patients receive...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Brain and Behavior |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/brb3.1461 |
| _version_ | 1818174469945950208 |
|---|---|
| author | Si‐Qia Chen Dong‐Yang Mao Dun‐Can Wei Wen‐Zhen He |
| author_facet | Si‐Qia Chen Dong‐Yang Mao Dun‐Can Wei Wen‐Zhen He |
| author_sort | Si‐Qia Chen |
| collection | DOAJ |
| description | Abstract Introduction To evaluate effectiveness of human urinary kallindinogenase (HUK) in patients with acute ischemic stroke (AIS) according to Chinese ischemic stroke subclassification (CISS) and analyzed risk factors of clinical efficacy. Methods In this retrospective study, 134 patients received conventional therapy were enrolled to control group, and 132 patients received HUK treatment were enrolled to HUK group. National Institute of Health Stroke Scale (NIHSS) score was used to evaluate the clinical efficacy. Multivariate analysis of risk factors was performed by using logistic regression. Results After treatment, NIHSS score of HUK group was significant lower than that of control group (p = .009). Effectiveness rate was 71.2% in HUK group, and 53.7% in control group, respectively (p = .003). The NIHSS of patients with large artery atherosclerosis (LAA) subtype in HUK group was significantly lower than that in control group (p = .005). The absence of HUK (OR = 2.75), homocysteine (OR = 0.15), and CS subtype (OR = 0.18) were risk factors for HUK clinical efficacy. Conclusions Human urinary kallindinogenase is an effective therapeutic approach for treatment of patients with AIS, especially in patients with LAA subtype. The absence of HUK, elevated homocysteine, and cardiogenic stroke subtype were risk factor for clinical efficacy of HUK. |
| first_indexed | 2024-12-11T19:44:54Z |
| format | Article |
| id | doaj.art-1e5a927a0ed24b7180bc280118d20e2a |
| institution | Directory Open Access Journal |
| issn | 2162-3279 |
| language | English |
| last_indexed | 2024-12-11T19:44:54Z |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Brain and Behavior |
| spelling | doaj.art-1e5a927a0ed24b7180bc280118d20e2a2022-12-22T00:52:56ZengWileyBrain and Behavior2162-32792020-01-01101n/an/a10.1002/brb3.1461Human urinary kallindinogenase therapy for acute ischemic stroke according to Chinese ischemic stroke subclassification: Clinical efficacy and risk factorsSi‐Qia Chen0Dong‐Yang Mao1Dun‐Can Wei2Wen‐Zhen He3Department of Neurology First Affiliated Hospital of Shantou University Medical College Shantou ChinaClinical Pharmacy First Affiliated Hospital of Shantou University Medical College Shantou ChinaDepartment of Pharmacy First Affiliated Hospital of Shantou University Medical College Shantou ChinaDepartment of Neurology First Affiliated Hospital of Shantou University Medical College Shantou ChinaAbstract Introduction To evaluate effectiveness of human urinary kallindinogenase (HUK) in patients with acute ischemic stroke (AIS) according to Chinese ischemic stroke subclassification (CISS) and analyzed risk factors of clinical efficacy. Methods In this retrospective study, 134 patients received conventional therapy were enrolled to control group, and 132 patients received HUK treatment were enrolled to HUK group. National Institute of Health Stroke Scale (NIHSS) score was used to evaluate the clinical efficacy. Multivariate analysis of risk factors was performed by using logistic regression. Results After treatment, NIHSS score of HUK group was significant lower than that of control group (p = .009). Effectiveness rate was 71.2% in HUK group, and 53.7% in control group, respectively (p = .003). The NIHSS of patients with large artery atherosclerosis (LAA) subtype in HUK group was significantly lower than that in control group (p = .005). The absence of HUK (OR = 2.75), homocysteine (OR = 0.15), and CS subtype (OR = 0.18) were risk factors for HUK clinical efficacy. Conclusions Human urinary kallindinogenase is an effective therapeutic approach for treatment of patients with AIS, especially in patients with LAA subtype. The absence of HUK, elevated homocysteine, and cardiogenic stroke subtype were risk factor for clinical efficacy of HUK.https://doi.org/10.1002/brb3.1461acute ischemic strokeChinese ischemic stroke subclassificationhomocysteinehuman urinary kallidinogenaselarge artery atherosclerosisrisk factor |
| spellingShingle | Si‐Qia Chen Dong‐Yang Mao Dun‐Can Wei Wen‐Zhen He Human urinary kallindinogenase therapy for acute ischemic stroke according to Chinese ischemic stroke subclassification: Clinical efficacy and risk factors Brain and Behavior acute ischemic stroke Chinese ischemic stroke subclassification homocysteine human urinary kallidinogenase large artery atherosclerosis risk factor |
| title | Human urinary kallindinogenase therapy for acute ischemic stroke according to Chinese ischemic stroke subclassification: Clinical efficacy and risk factors |
| title_full | Human urinary kallindinogenase therapy for acute ischemic stroke according to Chinese ischemic stroke subclassification: Clinical efficacy and risk factors |
| title_fullStr | Human urinary kallindinogenase therapy for acute ischemic stroke according to Chinese ischemic stroke subclassification: Clinical efficacy and risk factors |
| title_full_unstemmed | Human urinary kallindinogenase therapy for acute ischemic stroke according to Chinese ischemic stroke subclassification: Clinical efficacy and risk factors |
| title_short | Human urinary kallindinogenase therapy for acute ischemic stroke according to Chinese ischemic stroke subclassification: Clinical efficacy and risk factors |
| title_sort | human urinary kallindinogenase therapy for acute ischemic stroke according to chinese ischemic stroke subclassification clinical efficacy and risk factors |
| topic | acute ischemic stroke Chinese ischemic stroke subclassification homocysteine human urinary kallidinogenase large artery atherosclerosis risk factor |
| url | https://doi.org/10.1002/brb3.1461 |
| work_keys_str_mv | AT siqiachen humanurinarykallindinogenasetherapyforacuteischemicstrokeaccordingtochineseischemicstrokesubclassificationclinicalefficacyandriskfactors AT dongyangmao humanurinarykallindinogenasetherapyforacuteischemicstrokeaccordingtochineseischemicstrokesubclassificationclinicalefficacyandriskfactors AT duncanwei humanurinarykallindinogenasetherapyforacuteischemicstrokeaccordingtochineseischemicstrokesubclassificationclinicalefficacyandriskfactors AT wenzhenhe humanurinarykallindinogenasetherapyforacuteischemicstrokeaccordingtochineseischemicstrokesubclassificationclinicalefficacyandriskfactors |